Recent Updates
Recently added Catalysts

PF-06751979 single ascending dose

Phase 1

Healthy Subjects | Small molecule | Other |Pfizer, Inc.|Last Updated: Nov 1, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment55

FDA Designations

No designations recorded

Clinical trial landscape

PF-06751979 single ascending dose · 1 trial · 1 indication

Phase 1 1
NCT02509117First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979Healthy Subjects
COMPLETED55 Analytics
PHASE1COMPLETED
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
Healthy SubjectsUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part A: Baseline up to 47 days; Part B and C: Baseline up to 29 days

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the follow up visit (up to 47 days in Part A, 29 days in Part B and C), that were absent before treatment or that worsened relative to pretreatment state.

Number of Participants With Abnormal Physical Examinations Findings
Part A: Baseline up to 47 days, Part B and C: Baseline up to 29 days

A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Abnormality in physical examinations was based on investigator's discretion.

Number of Participants With Abnormal Neurological Examinations Findings
Part A: Baseline up to 47 days, Part B and C: Baseline up to 29 days

The neurological examination included the assessment of higher cortical function, the cranial nerves, motor function, deep tendon reflexes, sensory exam, and coordination and gait. Abnormality in neurological examinations was based on investigator's discretion.

Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline
Baseline

C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of "Yes" on "actual attempt"); preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome measure, number of participants with positive response (response of "yes") to suicidal behavior, ideation or any non-suicidal self-injurious behavior, at baseline were reported.

Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7
Day 7

C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of "Yes" on "actual attempt"); preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome, number of participants with positive response (response of "yes") to suicidal behavior, ideation or any self-injurious behavior, at day 7 were reported.

Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14
Day 14

C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of "Yes" on "actual attempt"); preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome, number of participants with positive response (response of "yes") to suicidal behavior, ideation or any self-injurious behavior, at Day 14 were reported.

Part B and C: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 19
Day 19

C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of "Yes" on "actual attempt"); preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome, number of participants with positive response (response of "yes") to suicidal behavior, ideation or any self-injurious behavior, at Day 19 were reported.

Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Part A: Baseline up to 47 days, Part B and C: Baseline up to 29 days

Criteria for clinically significant ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30 change \<60 or \>=60 msec from baseline.

Number of Participants With Laboratory Abnormalities
Part A: Baseline up to 47 days, Part B and C: Baseline up to 29 days

Abnormalities criteria:hematology(hemoglobin; hematocrit; RBC\<0.8\*lower limit of normal \[LLN\]; platelets\<0.5\*LLN,\>1.75\*upper limit of normal \[ULN\]; WBC\<0.6\*LLN,\>1.5\*ULN; lymphocytes; neutrophils; basophils; eosinophils; monocytes\<0.8\*LLN,\>1.2\*ULN; coagulation(prothrombin (PT); PT ratio\>1.1\*ULN), liver(bilirubin\>1.5\*ULN; aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase; gamma GT\>0.3\*ULN; protein; albumin\<0.8\*LLN,\>1.2\*ULN); renal(blood urea nitrogen, creatinine\>1.3\*ULN; uric acid\>1.2\*ULN); electrolytes(sodium\<0.95\*LLN,\>1.05\*ULN; potassium; chloride; calcium; bicarbonate\<0.9\*LLN,\>1.1\*ULN), chemistry(glucose\<0.6\*LLN,\>1.5\* ULN); urinalysis(pH \<4.5,\>8; glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte, esterase\>1; WBC; bacteria\>=20, epithelial cells\>=6; granular casts, hyaline casts, red cell casts, white cell casts\>1; lipids(cholesterol\[C\], LDL-C\>1.3\*ULN; HDL-C\<0.8\*LLN, triglycerides\>1.3\*ULN); hormones(T4, T3, T4, TSH\<0.8\*LLN,\>1.2\*ULN)

Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Part A: Baseline up to 47 days, Part B and C: Baseline up to 29 days

Following parameters were analyzed for examination of vital signs: supine systolic and diastolic blood pressure, pulse rate and body temperature.

Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry
Day 1

Continuous cardiac telemetry was conducted in participants. All abnormal cardiac rhythms were recorded and reviewed by the study physician for the presence of rhythms of potential clinical concern. In this outcome measure, number of participants who had cardiac rhythms of potential clinical concern (based on physician's discretion) were reported.

Secondary Endpoints

Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979
predose, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24, 36, 48 and 72 hours post dose on Day 1
Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979
predose, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24, 36, 48 and 72 hours post dose on Day 1
Part A: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979
predose, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24, 36, 48 and 72 hours post dose on Day 1
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Single Ascending Dose Cross-overEXPERIMENTALSingle Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
Multiple Ascending Dose PF-06751979EXPERIMENTALMultiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
Multiple Ascending Dose PlaceboPLACEBO_COMPARATORMultiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
Multiple Dose Elderly PF-06751979EXPERIMENTALMultiple dose administration to Healthy Elderly Subjects (PF-06751979)
Multiple Dose Elderly PlaceboPLACEBO_COMPARATORMultiple dose administration to Healthy Elderly Subjects (Placebo)

Interventions

NameTypeDescription
PF-06751979 single ascending doseDRUGPF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
Placebo single doseDRUGMatched Placebo solution/suspension administered as single dose.
PF-06751979 multiple ascending doseDRUGPF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
Placebo multiple doseDRUGMatched Placebo (solution/suspension)administered daily for 14 consecutive days.
PF-06751979 multiple doseDRUGPF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years or between the ages of 60 and 85 years, inclusive. * Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 lbs) at Screening. * Evidence of a persona...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about PF-06751979 single ascending dose

What is PF-06751979 used for?

PF-06751979 is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development, with a completed first-in-human trial evaluating single and multiple ascending doses. The drug is not approved and remains under investigation.

Who makes PF-06751979?

PF-06751979 is being developed by Pfizer, Inc. (NYSE: PFE). The company conducted a Phase 1 first-in-human study of the drug in healthy subjects in the United States.

What phase is PF-06751979 in?

PF-06751979 is in Phase 1 clinical development. A Phase 1 trial, NCT02509117, has been completed. The drug is investigational and has not been approved for any use.

What clinical trials is PF-06751979 in?

PF-06751979 has one completed Phase 1 trial, NCT02509117, titled 'First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979'. The trial enrolled 55 healthy subjects in the United States and was randomized, double-blind, and placebo-controlled.

Is PF-06751979 the same as another drug?

No alternative names for PF-06751979 have been disclosed. The drug is identified by its Pfizer compound number, PF-06751979, in clinical trial records.